Ucb

Ucb Liabilities

The The Liabilities of Ucb (UCB.BR) as of Nov 20, 2026 is 7.29 B EUR. In the previous year, The Liabilities was 7.32 B EUR — a change of -0.37% (lower).

Liabilities

7.29 BEUR

YoY

-0.37%

Last updated:

In 2025, Ucb's total liabilities amounted to 7.29 B EUR, a -0.37% difference from the 7.32 B EUR total liabilities in the previous year.

The Ucb Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
4.26 B EUR
Jan 1, 2019
4.07 B EUR
Jan 1, 2020
6.05 B EUR
Jan 1, 2021
5.82 B EUR
Jan 1, 2022
6.80 B EUR
Jan 1, 2023
6.56 B EUR
Jan 1, 2024
7.32 B EUR
Jan 1, 2025
7.29 B EUR
The Ucb Liabilities history
YEARLiabilitiesYoY
7.29 BEUR-0.37%
7.32 BEUR+11.49%
6.56 BEUR-3.53%
6.80 BEUR+16.83%
5.82 BEUR-3.69%
6.05 BEUR+48.50%
4.07 BEUR-4.39%
4.26 BEUR+1.87%
4.18 BEUR-11.70%
4.74 BEUR-12.48%
5.41 BEUR+2.89%
5.26 BEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ucb Stock analysis

What does Ucb do? The company UCB SA is a Belgian pharmaceutical company that was founded in 1928 and is now active worldwide. The business model of UCB SA is based on the discovery and development of medications for severe diseases. The core competencies of the company are in neurology, immunology, and cardiology. In the history of UCB SA, there are several milestones. In 1961, UCB SA succeeded in synthesizing antihistamines, which marked the beginning of the development of medications for allergic diseases. In the 1990s, UCB SA began to focus on the development of medications for the treatment of epilepsy and Parkinson's disease. In the 2000s, UCB SA acquired several companies, expanding its portfolio of medications and its geographic reach. The company operates three different divisions: pharmaceuticals, biopharmaceuticals, and specialty chemicals. In the pharmaceuticals division, UCB SA develops and distributes medications for the treatment of epilepsy, Parkinson's disease, and autoimmune diseases such as rheumatoid arthritis and lupus. UCB SA's biopharmaceutical division focuses on researching antibodies for the treatment of various diseases such as cancer and multiple sclerosis. In the specialty chemicals division, UCB SA produces chemical products such as solvents and paints. The company offers a wide range of products tailored to the needs of patients with various diseases. One example of a well-known product from UCB SA is Keppra, a medication for the treatment of epilepsy. Keppra is one of the most prescribed medications for epilepsy and has helped improve the lives of millions of patients. Another example is Cimzia, a medication for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Cimzia belongs to a new generation of medications that aim to selectively influence the immune system and thus inhibit inflammation. UCB SA places great value on innovation and constantly researches new medications and therapies. The company has a strong research and development team with over 3,000 employees and invests approximately 25% of its revenue annually in the research and development of new medications. Overall, UCB SA is an innovative and successful pharmaceutical company with a broad portfolio of medications and a strong commitment to the quality of the products developed. The company is dedicated to improving the lives of patients with severe diseases and remains a key player in the global pharmaceutical industry in the long term. Ucb is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Ucb's Liabilities

Ucb's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ucb's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ucb's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ucb's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ucb’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ucb stock

The Liabilities of Ucb is 7.29 B EUR in 2025.

The Liabilities of Ucb changed from 7.32 B EUR to 7.29 B EUR, representing a -0.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Ucb since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Ucb historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ucb

All Key Metrics — Ucb